Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

This early-phase study is testing a new type of immunotherapy — injecting a self-amplifying RNA (saRNA) particle that produces a protein called IL-12 directly into tumors — to stimulate the immune system to fight head and neck cancer. **You may be eligible if...** - You have head and neck cancer that cannot be removed surgically, or that has recurred or spread, and you have at least one tumor that can be injected - You have received prior treatment including platinum chemotherapy, 5-fluorouracil, taxane, cetuximab, or gemcitabine - You have also received prior anti-PD-1 or anti-PD-L1 immunotherapy - You have progressed after these treatments **You may NOT be eligible if...** - You have not received the required prior treatments - You have active autoimmune disease - You have serious infections or other conditions that make participation unsafe Talk to your doctor to see if this trial is right for you.